Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-019260
Filing Date
2025-02-12
Accepted
2025-02-12 21:18:10
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 16591
2 EX-1 ck0001669811-ex1.pdf EX-1 12792
  Complete submission text file 0000950170-25-019260.txt   36108
Mailing Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071 213-830-6300
Oaktree Acquisition Corp. III Life Sciences (Subject) CIK: 0002029769 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94673 | Film No.: 25616862
SIC: 6770 Blank Checks
(CF Office: 05 Real Estate & Construction)

Mailing Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071 213-830-6300
Oaktree Acquisition Holdings III LS, LLC (Filed by) CIK: 0002037181 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G